Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.